This is an international, phase 3, randomized trial of Autologous Dendritic cell immunotherapy (AGS-003) Plus standard Treatment of advanced renal cell carcinoma (ADAPT), sponsored by Argos Therapeutics, Inc. Cells collected from a person's own kidney tumor can be combined with AGS-003 to create a personalized, experimental drug. Participants will be randomized to either the control group or the experimental group. The control group will receive sunitinib, the standard and most commonly prescribed treatment, while the experimental group will be given the immunotherapy treatment, AGS-003, plus sunitinib.
Patients with newly diagnosed, advanced kidney cancer can participate in this research. For more information about cancer research, click here.